X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Dotinurad
Therapeutic Area: Rheumatology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Eisai
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 25, 2020
Details:
Under this agreement, Eisai will proceed with the development of dotinurad in China.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
